{"filing":{"accession_number":"0001193125-26-400144","cik":"0001789972","ticker":"CGEM","company_name":"Cullinan Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-24","primary_document":"cgem-20260924.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526400144/cgem-20260924.htm"},"events":[{"id":34726,"run_id":31971,"accession_number":"0001193125-26-400144","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Cullinan Therapeutics disclosed anticipated clinical trial milestones and data presentation timelines for Q4 2026 across its T cell engager pipeline (CLN-978, velinotamig, CLN-049), including specific dates for data releases and conference presentations.","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38547,"accession_number":"0001193125-26-400144","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Cullinan Therapeutics disclosed anticipated clinical trial milestones and data presentation timelines for Q4 2026 across its T cell engager pipeline (CLN-978, velinotamig, CLN-049), including specific dates for data releases and conference presentations. This is a forward-looking operational disclosure of clinical development progress rather than a completed event, earnings release, or other material event type. While material to investors assessing pipeline progress, it is primarily a strategic/operational communication of anticipated milestones rather than a discrete material event that has occurred.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T12:21:00.525261+00:00","company_name":"","ticker":null,"filing_date":""},{"id":38548,"accession_number":"0001193125-26-400144","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This disclosure announces planned clinical trial data presentations and milestones for Q4 2026 across three T cell engager programs (CLN-978, velinotamig, CLN-049) in immunology and oncology. While the company is advancing its pipeline, this is a forward-looking announcement of anticipated data-sharing events rather than disclosure of actual clinical results, regulatory decisions, or material operational changes. The filing contains standard forward-looking statement disclaimers and does not report completed events or material developments that would immediately affect investor assessment of the company's financial condition or prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T12:21:00.525261+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38547,"accession_number":"0001193125-26-400144","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Cullinan Therapeutics disclosed anticipated clinical trial milestones and data presentation timelines for Q4 2026 across its T cell engager pipeline (CLN-978, velinotamig, CLN-049), including specific dates for data releases and conference presentations. This is a forward-looking operational disclosure of clinical development progress rather than a completed event, earnings release, or other material event type. While material to investors assessing pipeline progress, it is primarily a strategic/operational communication of anticipated milestones rather than a discrete material event that has occurred.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T12:21:00.525261+00:00","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-09-24"},{"id":38548,"accession_number":"0001193125-26-400144","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This disclosure announces planned clinical trial data presentations and milestones for Q4 2026 across three T cell engager programs (CLN-978, velinotamig, CLN-049) in immunology and oncology. While the company is advancing its pipeline, this is a forward-looking announcement of anticipated data-sharing events rather than disclosure of actual clinical results, regulatory decisions, or material operational changes. The filing contains standard forward-looking statement disclaimers and does not report completed events or material developments that would immediately affect investor assessment of the company's financial condition or prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T12:21:00.525261+00:00","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-09-24"}]}